Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCR versus FCR for initial therapy of Waldenstrom macroglobulinaemia
2011-005156-34Phase 2Terminated
- Sponsor
- University College London
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, cyclophosphamide, rituximab, fludarabine in Waldenström macroglobulinemia (WM), sponsored by University College London. Started Jul 2012; status: terminated.
02
Drugs
bortezomibcyclophosphamiderituximabfludarabine
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2011-005156-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005156-34.